Pharmacological Preconditioning by Incretinomimetics Exenatide and Vildagliptin: Decrement of Liver Ischemia-reperfusion Injury
Keywords:
Ischemia-reperfusion, Liver, Incretinomimetics, Exenatide, Vildagliptin, Hepatoprotection.Abstract
Introduction: Experimental and clinical data accumulated over the past decade indicate a number of pleiotropic effects
that are inherent in incretinomimetics. These effects are due to the wide distribution of GLP-1 receptors (GLP-1R) in many
organs and tissues.
Objective: Study of hepatoprotective activity of exenatide and vildagliptin on the liver ischemia/reperfusion model, taking
into account biochemical and morphological parameters.
Methods: Ischemia-reperfusion injury of the liver was reproduced by 15-minute clamping of the rat liver-duodenal
ligament analogue with subsequent restoration of blood flow and removal of the animal from the experiment on the 3rd
day. Exenatide at a dose of 10 μg/kg was administered subcutaneously, vildagliptin orally at a dose of 0.2 mg/kg 2 hours
before the experiment.
Results: Exenatide (10 μg/kg) and vildagliptin (0.2 mg/kg) reduced hepatocellular ischemia/reperfusion injury, which
resulted in preventing the increased activity of AST and ALT transaminases, reducing necrosis areas by 1.9 times
(compared with the ischemia/reperfusion group), reducing the infiltration of stromal and parenchymal elements of the liver,
reducing edema.
Conclusion: The hepatoprotective effects of exenatide and vildagliptin identify them as potentially effective drugs for
correcting ischemic/reperfusion injury of the liver.
